Tumor vaccines and gene therapy have received significant attention as means of increasing cellular and humoral immune responses to cancer. We conducted a pilot study of seven research dogs to determine whether intradermal injection of canine tumor cells transfected via the Accell particle-mediated gene transfer device with the cDNA for human granulocyte-macrophage colony-stimulating factor (hGM-CSF) would generate biologically relevant levels of protein and result in demonstrable histological changes at sites of vaccination. Tumor cell vaccines of 10 7 irradiated canine melanoma cells were nontoxic, safe, and well tolerated. No significant alterations in blood chemistry values or hematological profiles were detected. A histological review of control vaccine sites revealed inflammatory responses predominated by eosinophils, whereas vaccine sites with hGM-CSF-transfected tumor cells had an influx of neutrophils and macrophages. Enzyme-linked immunosorbent assays of skin biopsies from vaccine sites had local hGM-CSF production (8.68 -16.82 ng/site of injection) at 24 hours after injection and detectable levels (0.014 -0.081 ng/site) for Յ2 weeks following vaccination. Flow cytometric analysis of hGM-CSF-transfected cells demonstrated Յ25% transfection efficiency, and hGM-CSF levels obtained during time-course assays demonstrated biologically relevant levels for both irradiated and nonirradiated samples. These data demonstrate the in vivo biological activity of irradiated hGM-CSF-transfected canine tumor cells and help provide evidence for a valid translational research model of spontaneous tumors.
I mmunotherapy using both nonspecific stimulation and the specific administration of cells or secreted products has gained recognition for its potential usefulness in diseases that are resistant to traditional therapy. The potential benefits of using irradiated tumor cell vaccines to stimulate potent, long-lasting, and specific immunity have been documented in several human and animal trials. [1] [2] [3] [4] [5] [6] Some of these trials used cytokines to increase tumor antigen (Ag) recognition and cytolytic activity against specific tumor-associated Ags. 1, [7] [8] [9] [10] [11] However, a systemic administration of cytokines is associated with significant toxicity and requires frequent administration of the cytokine attributable to short half lives in vivo. [12] [13] [14] [15] A cytokine-producing tumor vaccine may circumvent these difficulties, as cytokine-gene-engineered vaccines can provide local, prolonged production of immunomodulatory protein products, resulting in potential hostmediated antitumor activity. 3,16 -19 Accell (PowderJect Vaccines, Madison, Wis) particlemediated gene transfer uses cDNA-coated gold beads bombarded directly into cells or tissue via specifically targeted, high-pressure, helium pulses; several studies have been conducted to demonstrate the speed and efficacy of this method of mechanical gene transfer. 20 -25 Stable, reproducible, and high levels of expression have been obtained using a wide variety of cDNAs, tissues, cell types, and species. 26 -30 Dual expression of separate plasmid vectors within the same cell has been demonstrated. 31 Protective immunity to several viral diseases has been obtained following Accell delivery of genes encoding viral proteins, [32] [33] [34] [35] [36] [37] and antitumor effects in animals have been observed using specific cytokine genes. 7, 9, 28, 29 Granulocyte macrophage-colony stimulating factor (GM-CSF) is a pluripotent, naturally occurring growth factor produced by T cells, B cells, macrophages (M), mast cells, endothelial cells, and fibroblasts in response to different immune or inflammatory stimuli. 38, 39 Clinical applications of GM-CSF include ameliorating che-motherapy-associated neutropenia as well as enhancing hematopoietic recovery after bone marrow transplantation. 40 -42 GM-CSF can activate neutrophils, eosinophils, and M to lyse tumor cells directly or to mediate antibody-dependent cellular cytotoxicity. 38, 39, [43] [44] [45] It can also increase major histocompatability complex expression of tumor Ag to immune effector cells, because GM-CSF is important in the maturation and function of bone marrow-derived dendritic cells. These dendritic cells are believed to be professional Ag-presenting cells capable of presenting Ag to unprimed CD4 ϩ as well as CD8 ϩ T cells. 46 -48 Following administration either systemically or in a vaccine fashion, GM-CSF can induce antitumor immunity in many model systems, including the nonimmunogenic F10 variant of B16 melanoma. 1, 7, 49 Additional research has compared the ability of 22 different molecules to stimulate systemic antitumor immunity, and GM-CSF was shown to be the most effective. 50 Our research group has demonstrated previously the effects of hGM-CSF when administered to dogs either in the context of Accell in vivo transfection into normal skin and oral mucosa or direct subcutaneous administration of the functional hGM-CSF protein. 27, 51 Direct bombardment resulted in functional protein production and local histopathological changes associated with hGM-CSF. When administered subcutaneously, blood monocyte and lymphocyte numbers increased, and monocyte antitumor cytostasis activity was enhanced. This current study addresses the administration of hGM-CSF in the context of ex vivo cytokine-gene-engineered tumor cells. Finally, GM-CSF enhances the function of differentiated cells, prolongs the survival of mature neutrophils and eosinophils, and is thought to enhance the ability of cells to respond to secondary stimuli, resulting in increased superoxide production, leukotriene synthesis, and arachidonic acid release. The consequence of these actions is to increase the phagocytic capabilities of relevant cell populations. 39 Melanomas in dogs provide a translational research model, as cutaneous and oral melanomas are the fourth most common cancer in dogs. 52, 53 Mucosal melanomas are highly metastatic and have a poor prognosis in the higher grades and stages. 54, 55 As is the case for advanced melanoma in humans, melanoma in dogs is generally resistant to chemotherapy and radiation therapy, and metastasis is the major cause of treatment failure and death. 56 -58 Finally, the dog offers a good translational model because of its large size, spontaneous development of tumors, rapid assessment of therapeutic activity, and biological similarity to humans. 59, 60 Based on these data, we initiated preclinical studies in normal dogs using an established canine melanoma cell line, CML-6M. Tumor cells were irradiated, Accelltransfected with hGM-CSF, ␤-galactosidase (␤-gal), or nontransfected, and administered intradermally (i.d.). In addition, canine cell lines were transfected in vitro, and the effects of cytokine or control cDNA were studied in reporter gene assays, flow cytometric analysis, and time course studies. The speed of vaccine creation, ease of vaccine administration, and demonstrated biological effects of hGM-CSF-transfected tumor cells demonstrate the potential clinical applications of these techniques in cancer immunotherapy.
MATERIALS AND METHODS

hGM-CSF and reporter gene constructs
The hGM-CSF plasmid constructs have been described previously. 7, 61 The reporter gene constructs pCMV-b and pCMVluc were driven by the cytomegalovirus immediate-early gene enhancer/promoter in a pNASS vector. Plasmids were grown in DH5a Escherichia coli and purified using Qiagen columns (Qiagen, Chatsworth, Calif). Purified DNA was further treated to eliminate endotoxin contamination. 62 
Preparation of gold beads
Following the methods reported previously, 21 ,63 a mixture of 175 g of cDNA and 70 mg of gold particles in 250 L of 0.05 M spermidine (catalog no. S-0266, Sigma, St. Louis, Mo) was added to 250 L of 10% CaCl 2 . The cDNA/gold particle precipitates were washed several times with 100% ethanol and resuspended at a density of 1 mg particles/mL ethanol; next, 100 L of polyvinylpyrrodine was added, and the slurry was allowed to deposit evenly on the lumen of tefzel plastic cartridges and dried with nitrogen. These conditions result in a delivery of 0.5 mg of gold and 1.25 g of DNA per transfection. Tubes were stored desiccated at Ϫ20°C until time of use.
Cell lines
Two adherent canine melanoma cell lines (CML-6M and CML-1), originally established from primary melanoma tumor samples (kindly provided by Dr. Lauren Wolfe, Auburn University, Auburn, Ala), were used for the procedures. 64 Growth media consisted of Leibovitz's L-15 medium (catalog no. 11415-023, Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES), and 1% penicillin-streptomycin-fungizone. Cells were grown to confluent monolayers in standard plastic flasks at 37°C in humidified 5% CO 2 and passaged when necessary. Only cells of Ͻ25 passages were used in the assays.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and clonogenic assays
To determine which canine melanoma cell line would be used for the vaccine studies, two canine melanoma cell lines were grown in culture, trypsinized, washed, and counted. A total of 10,000 cells in 200 L of growth media were plated per well into 96-well, flat-bottom plates in replicates of five per radiation treatment dose (1, 2.5, 5, 7.5, 10, 30, 50, 75, and 100 Gy) and incubated at 37°C in humidified 5% CO 2 . One plate from each cell line was sera-starved (0% FBS) for 24 hours to synchronize the cell populations, whereas the others were allowed to continue growing in standard growth media. 65, 66 After 4 days of incubation, 50 L of 2 mg/mL MTT (Sigma) was added to each well and incubated for 4 hours at 37°C; all supernatant was aspirated. A total of 100 L of dimethylsulfoxide was added to each well and shaken, and optical absorbance was read at 570 nm. 67, 68 Clonogenic assays were conducted by irradiating the two lines at the same doses and plating onto 100-mm dishes (Falcon 1001, Lincoln Park, NJ). Colonies were counted after 2 weeks of incubation and staining with 10% crystal violet. 69 
Preparation of target plates for Accell transfection
Cells were trypsinized from confluent flasks, washed with the growth media described above, centrifuged at 1000 revolutions per minute for 5 minutes, counted by trypan blue exclusion, and resuspended in 10 mL of media. Samples used in vaccination were irradiated at 100 Gy with a Cesium-137 radiation source under fully oxygenated conditions. All cells were centrifuged and resuspended at 1 ϫ 10 6 cells per 20 L of media and HEPES buffer. These cells were then spread out to a 1.5-cm circle on the sterile target plate and transfected with the Accell device at 250 pounds per square inch (psi) using either hGM-CSF or ␤-gal. These Accell transfection conditions have been reported in numerous papers as being the most effective for a wide variety of cell types, and we confirmed this finding in the dog system through dose-response assays using the reporter gene luciferase. 23, 70, 71 Cells were then collected from the target plates using repeated media rinses and cell scrapers and pooled based on treatment in preparation for vaccination. Cell viability was usually Ͼ90% as determined by trypan blue exclusion.
Luciferase detection
Cells were transfected as described above, and luciferase activity detected as reported previously, 20 with the following minor noted modifications. Briefly, 200 L of extraction buffer (potassium phosphate, protease-free bovine serum albumin (BSA), phenylmethylsulfonylfluoride, and dithiothreitol) was added to the transfected and washed cells following 12-24 hours of incubation. A total of 1 L was then added to 80 L of 5ϫ reaction buffer (glycylglycine (pH 7.8), MgCl 2 , BSA, and adenosine 5Ј-triphosphate) and 119 L of distilled water. The samples were vortexed, and 300 L of luciferin solution was added (luciferin, distilled water, and NaHCO 3 ) before analysis. Light emittance was measured using a Berthold Lumat LB9501 luminometer (EG&G Berthold, Wellesley, Mass).
Flow cytometry staining
Intracellular cytokine staining involves initial fixation of cells in paraformaldehyde to cross-link proteins and prevent their leakage. The cellular membranes are permeabilized with a mild detergent, generating gaps that allow fluorochromeconjugated monoclonal antibodies access to the cell interior. The resulting labeled cells are indicative of cytokine production, allowing the classification of individual cells according to their cytokine production pattern. Intensity of staining is proportional to Ag content. Protocol for hGM-CSF staining was as follows: cell suspensions were washed twice in balanced salt solution (BSS) with 0.01% HEPES buffer, 1% FBS, and 0.1% sodium azide before fixing with 500 L of 4% paraformaldehyde, which was allowed to incubate for 10 minutes. Next, cells were washed twice in BSS containing 0.005% saponin to permeabilize the cell membranes. Alternative permeabilization with Permafix (catalog no. 77599, Ortho Diagnostic Systems, Raritan, NJ) involved adding 2 mL of Permafix to 100 L of 1 ϫ 10 6 cells and incubating at room temperature for 1 hour. Biotinylated antibody (catalog no. 11022C (biotin rat IgG2A K for isotype control) or catalog no. 185920 (antihGM-CSF), both from PharMingen, San Diego, Calif) was added to 250,000 cells in 100 L of BSS-saponin and allowed to incubate at room temperature for 45 minutes. Samples were washed twice in BSS-saponin and subsequently incubated with streptavidin-conjugated phycoerythrin (ϳ0.5 g/1 ϫ 10 6 cells) for 30 minutes at room temperature followed by two washes in BSS-saponin. Vimentin (catalog no. 1112-457, Boehringer Mannheim, Indianapolis, Ind) was used to demonstrate membrane permeabilization. Samples were stored dark and were refrigerated until analysis. All samples were analyzed using a Becton Dickinson FACScan flow cytometer (Mountain View, Calif), and data were processed using the WINMDI software program (The Scripps Research Institute, La Jolla, Calif).
Animals and assessment of treatment responses
A total of seven, normal, healthy beagle or hound crosses (ranging in age from 3 to 6 years) were used. All dogs were heartworm negative, free of ectoparasites and endoparasites, and housed in an American Association for the Accreditation of Laboratory Animal Care-approved vivarium. All animals were subjectively evaluated before treatment and daily during treatment for changes in eating or drinking and for behavioral changes related to pain or toxicity. Objective measurements included temperature, pulse, respiration, and body weight. Complete blood counts, blood chemistry panels, sera samples, and skin biopsies at the sites of vaccination were taken in accordance with the established protocol schema described above. Biopsy samples were split in half with a No. 10 scalpel blade; half were placed into formalin for histological analysis, whereas the remaining half were placed into 300 L of general extraction buffer containing Pefablock (Boehringer Mannheim), phosphate-buffered saline (PBS), 10% Triton X-100, BSA, and dithiothreitol for future hGM-CSF enzyme-linked immunosorbent assay (ELISA). ELISA samples were stored frozen at Ϫ80°C until the time of analysis. Biopsy sites were closed using 3-0 nylon in simple cruciate patterns. All protocols and procedures were approved by the University of Wisconsin Research Animal Resource Center.
Vaccine preparation and vaccination procedure
Transfected and control nontransfected cells were washed with PBS and concentrated to 1 ϫ 10 7 cells per 100 L. Recipient animals were sedated with ketamine (5 mg/kg) and valium (0.5 mg/kg) and shaved on the flank around the area of vaccination to facilitate easier assessment of local reaction; next, i.d. injections with a 27-gauge needle in a 1-mL tuberculin syringe were made.
The initial aspect of this study involved four dogs: two were given a dose of 10 7 hGM-CSF-transfected, irradiated, CML-6M tumor cells administered i.d. in two sites in the thoracic region; another two dogs were vaccinated in two sites with 10 7 control nontransfected, 100 Gy-irradiated, CML-6M cells. Vaccination sites were biopsied on days 1 and 7. A second vaccination (10 7 cells, one site) was performed on day 14 and biopsied on day 28. Complete blood counts, sera chemistry panels, single-blinded histopathological review, and hGM-CSF ELISAs were conducted at days 1, 7, and 28.
The second aspect of this study used three normal dogs inoculated with 10 7 hGM-CSF-transfected, 100 Gy-irradiated cells in two i.d. sites on the right side and inoculated with 10 7 ␤-gal-transfected, irradiated cells in two i.d. sites on the left side. Skin biopsy samples were taken on days 1 and 7. The animals were revaccinated on day 7 with 10 7 cells (one site each for hGM-CSF-or ␤-gal-transfected cells) and were treated as described above. Biopsies were obtained on day 21, and ELISAs and histopathological review were performed.
Time course assays
The two canine melanoma cell lines were transfected in triplicate in suspension using six-well plates (Falcon 3046) (1 ϫ 10 6 /well), as described above. Supernatant samples were collected in both independent and cumulative fashions in 12-hour increments. Independent timepoint samples had 2 mL of fresh growth media added at each timepoint. Protein levels of hGM-CSF in the supernatant were determined using ELISA.
ELISA methods
Levels of hGM-CSF for the time course experiments were determined using rat anti-hGM-CSF (catalog no. 18581D, PharMingen), biotin rat anti-hGM-CSF (PharMingen, 18592D), streptavidin-horseradish peroxidase conjugate (catalog no. 43-4323, Zymed, San Francisco, Calif), and tetramethylbenzidine substrate (S1600, Dako, Carpinteria, CA). Sensitivity using plates prepared in this manner was 56 pg/mL. 7 The samples tested were 1 mL of media taken at various timepoints. Cell lysates were obtained using 250 L of general extraction buffer at the same timepoints.
Commercial hGM-CSF ELISA kits (catalog no. KHC2012, Biosource, Camarillo, Calif) were used to assay all biopsy and sera samples because of increased sensitivity (10 pg/mL). Biopsy samples were minced and brought to 1-mL volumes with PBS. The standard kit protocol was followed for all samples and assayed in duplicate. Canine GM-CSF does not cross-react in either assay. 27 
Histopathology
Punch biopsy samples were placed in 10% formalin until routine processing. Samples were blocked in paraffin, cut into 5-m sections, and stained with hematoxylin and eosin. All samples were interpreted by a veterinary pathologist (R.R.D.) who was blinded to treatment. In an effort to quantitate the inflammatory responses, an objective determination of the greatest area of inflammatory or liquifactive necrosis was calculated through microscopy by measuring the largest areas of visible cell destruction (also in a single-blinded fashion).
Statistical methods
Protein expression levels for control-and hGM-CSF-transfected cells (for both in vitro and in vivo samples) as well as cell proliferation responses were all assessed using the repeated measures test. A P value of Ͻ.05 was considered significant.
RESULTS
Optimization of Accell transfection in canine cell lines
Two established canine lines, CML-1 and CML-6M, were transfected with luciferase cDNA and assayed for luciferase expression after 24 hours. The expression levels of the two cell lines at differing psi is shown (Fig  1) . Different DNA loading doses were also studied, and little difference was observed using all standard bead preparation dose levels. It is interesting to note the differences in expression between the highly metastatic line CML-6M and the nonmetastatic line CML-1. 64 We are attempting to determine whether this trend of increased expression in highly metastatic cells holds true in other canine cell lines and primary tumor samples.
Flow cytometry demonstrates hGM-CSF protein production in canine cells
To demonstrate a biological production of hGM-CSF protein product following Accell transfection, CML-6M and CML-1 canine melanoma cell lines were transfected and examined by intracellular cytokine staining. Vimentin was used as a positive control and demonstrated permeabilization of the cellular membranes using either method (Fig 2a) . Luciferase or ␤-gal reporter genetransfected cells were compared with hGM-CSF-transfected cells to demonstrate that the process of particle bombardment alone did not result in peak shifts and to determine the percentage of cells staining positive for hGM-CSF (Fig 2b) . The viability and integrity of the hGM-CSF-transfected cells were comparable with the control-transfected population. Similar results were obtained using both techniques of permeabilization. Transfection efficiencies of between 10% and 25% were observed in the canine cell lines. hGM-CSF staining of the control-transfected canine cells alone did not result in nonspecific binding, although the process of transfection and gold bead penetration does result in an alteration of autofluorescence compared with the isotype control.
Irradiation of canine cells induces reproductive cell death while maintaining protein production MTT proliferation and clonogenic assays were used to study reproductive cell death following irradiation. Melanoma cells (CML-1 and CML-6M) were exposed to various radiation doses (0 -100 Gy) using a Cesium-137 radiation source. Clonogenic assays were incubated for 2 weeks, and colonies were counted by staining with crystal violet. No colonies were observed at any radiation levels of Ͼ10 Gy (data not shown). The MTT assays revealed significant proliferative reductions at Ͼ5 Gy for the CML-1 line and at 10 Gy for the CML-6M line (Fig  3) . Similar results were seen with both sera-starved samples as well. Taken together, these data demonstrate that the radiation dose of 100 Gy that was administered is sufficient to arrest cell growth while permitting the safe, biologically active administration of genetically modified canine tumor cells.
Canine melanoma cell lines express high levels of hGM-CSF as detected by ELISA during time course assays CML-6M and CML-1 cells were transfected as described previously, and supernatant samples from separate cultures were obtained at indicated timepoints. hGM-CSF protein expression was quantified (ng/10 6 cells/timepoint) for both lines using ELISA (Fig 4) . Importantly, total hGM-CSF protein expression was similar for both irradiated and nonirradiated cells. It is our experience that canine cells transfect and express well using the Accell gene delivery device and human cytomegalovirus promoters. Transfection efficiency and expression was highest in the CML-6M line. This observation, in combination with the luciferase and flow cytometric analyses, led us to decide that this line should be used for our ex vivo vaccine protocol in normal dogs.
Ex vivo vaccines produce noticeable inflammatory responses compared with controls
At 24 hours, mild induration, erythema, and pruritus at sites of hGM-CSF-transfected tumor cell injection were noted. All were mild and within acceptable limits. These responses were noticeably greater than those observed at sites injected with the control-or ␤-gal-transfected cells. It was difficult to locate control samples for the third biopsy (days 21 or 28), because the inflammatory response was very mild, with little evidence of an eschar. However, hGM-CSF-transfected samples were more easily located at all timepoints because of the presence of eschars and a continued mild inflammatory response.
Histopathological evaluation of the hGM-CSF-transfected cell injection sites demonstrated prominent neutrophilic infiltrate, lymphocytes, and M adjacent to the tumor cells and spreading beyond the dermis into the subcutaneous tissue. Disruption of collagen bundles, follicular atrophy, and a diffuse inflammatory necrosis were also evident by day 7. In contrast, the control ␤-gal-transfected or nontransfected samples revealed moderate eosinophilic infiltrate and minimal neutrophil and M infiltration away from the site of injection. Furthermore, collagen bundles remained intact and no necrotic inflammation was apparent (Fig 5, A-C) . Tumor cells were evident at the injection site for ϳ7 days after vaccination, and little evidence of their presence was found after 14 days (Fig 5D) . Representative examples for all experimental groups are illustrated. In an effort to objectively measure the differences between sites, the greatest area of inflammatory or liquifactive necrosis was calculated through microscopy and summarized for the first study of day 7 biopsy samples (Tables  1 and 2 ). This method was used because an accurate assessment and counting of intact cell populations was difficult in hGM-CSF-transfected tumor cell vaccine sites by day 7. Overall, tumor vaccine injections and transfected cell doses were well tolerated; all clinical assessments were within normal limits.
In vivo hGM-CSF protein production at sites of vaccination To evaluate in vivo hGM-CSF production levels at sites of vaccination, skin punch biopsy samples were collected with 8-mm punches and split in half for analysis. ELISAs demonstrated ranges of 8.68 -16.82 ng and a mean concentration of 12.58 ng of hGM-CSF/million cells/24 hours in vivo at sites of injection (Tables 3 and 4) . These concentrations decreased to a mean of 0.21 ng by day 7 and 0.01 ng by day 28, reflecting the transient transfection induced by the Accell transfer method. However, the hGM-CSF cDNA 3Ј alterations confer significantly greater, and longer lasting, expression than does standard hGM-CSF or a simple injection of protein product. 60, 72 No hGM-CSF was detected in any sera samples collected in animals at any of the indicated timepoints. These ranges and the duration of expression observed in the research dogs are actually preferred for immunological effects rather than hematopoietic effects of GM-CSF.
73
DISCUSSION
Using an established canine melanoma cell line in normal dogs, we have demonstrated that an irradiated, hGM-CSF cytokine-gene-engineered melanoma cell vaccine, incapable of cell proliferation, was able to produce hGM-CSF at the site of injection for an extended period and was clinically well tolerated. Using the Accell gene transfer device, we determined optimal gene transfer conditions for hGM-CSF cDNA into canine melanoma cell lines and demonstrated that these cytokine-gene-modified cells can produce a functional protein product. Although transfection and protein expression are transient using this method of gene transfer, we have shown biologically relevant levels of cytokines in vivo at the sites of vaccination with irradiated, transfected tumor cells.
Cell viability and proliferation assays demonstrated that previously published and accepted levels of irradiation induce reproductive cell death in canine cells, without any inhibitory effects on the synthesis of the hGM-CSF protein product, both in vitro and in vivo. 1 Therefore, the irradiation of tumor cell lines seems to have a negligible effect on cytokine production, and has been reported by some investigators to actually increase total protein production over time. 7 These assays address a major concern with any tumor vaccine protocol: CML-6M and CML-1 cells were transfected as described previously, and supernatant was collected from separate cultures at 12, 24, 36, 48, 60 , and 72 hours in a cumulative fashion for both irradiated and nonirradiated samples of each line. Thus, the 12-hour samples represent hGM-CSF production accumulated over 12 hours, 24-hour samples represent accumulation over 24 hours, and so forth. ELISAs were conducted as described previously. CML-6M (stippled bars, nonirradiated; open bars, irradiated) proved to be a significantly higher expresser of hGM-CSF than did CML-1 (filled bars, nonirradiated; cross-hatched bars, irradiated); ‫ء‬ indicates significance (P Ͻ .05).
the induction of reproductively viable tumor cells into a vaccine site.
hGM-CSF vaccine injection sites grossly differed from control sites in the degree of inflammation and in the appearance of eschar at the injection areas. Controltransfected or nontransfected irradiated tumor cells had noticeably less inflammation at 24 hours after injection than did the hGM-CSF vaccine sites, and it was difficult to discern these control sites 7 days after the injection of cells.
Our most exciting results in this preclinical study were the obvious differences in inflammatory responses and the presence of follicular atrophy observed between animals in the first in vivo experiment and between treatment sites in the second in vivo experiment. Neutrophils, lymphocytes, and M dominated the inflamma- 10 7 ) were administered i.d. and biopsied on days 1, 7, and 28. Representative sections are presented. Similar results were observed for both ␤-gal-transfected controls and for nontransfected control samples. A: ϫ250 magnification of a control nontransfected, irradiated tumor cell site biopsy at 7 days after injection. The insert is a higher magnification of the eosinophils obtained from the indicated area, and the arrowhead points to an eosinophil, B: Day 7 hGM-CSF-transfected tumor cell vaccination site biopsy at ϫ250 magnification. The insert is a higher magnification of M (black arrowhead) and lymphocytes (white arrowhead). C: Day 7 hGM-CSF-transfected tumor cell vaccination site biopsy at ϫ250 magnification. The insert is a higher magnification of an intact tumor cell (black arrowhead) and neutrophils (white arrowhead). D: Day 1 irradiated, hGM-CSF-transfected tumor cells at the site of injection (ϫ400 magnification). Darkly basophilic staining cells are the tumor cells. The white arrowhead points to an intact tumor cell, and the black arrowhead demonstrates a representative gold bead that seems to be associated with the nucleus of the injected tumor cell. tory response seen at hGM-CSF sites, which contrasted sharply with the control ␤-gal-transfected or nontransfected irradiated melanoma tumor cell injection sites. This was true for both numbers of inflammatory cells and in the induction of diffuse necrotic inflammation. Sites injected with ␤-gal-transfected or nontransfected tumor cells had similar histological appearances in vivo following vaccination. Our results are consistent with the findings of several other groups using GM-CSF transfection, including Dranoff et al, 1 Mahvi et al, 7 Rajagopalan et al, 61 and Wakimoto et al. 74 These authors found minimal infiltration at sites of control tumor cell vaccination, whereas significant lymphocyte and M infiltration was observed at sites of hGM-CSF-transfected tumor cell administration.
The disruption of collagen bundles and generalized necrotic inflammatory processes that we observed were likely attributable to the release of protease-containing granules from the infiltrating neutrophils and M. This effect was not observed in the control sites, because the numbers of neutrophils were much less than at the hGM-CSF sites. Furthermore, we hypothesize that the predominant eosinophilic response at control sites may be a reflection of the typical inflammatory response, where eosinophils and other polymorphonuclear cells are among the first cells to respond to an irritant. Without the driving force of a T helper 1 cytokine (in our case hGM-CSF) to bring in additional polymorphonuclear cells, only moderate levels of inflammatory cells are present and a T helper 2 response may exist. The acute inflammatory response at the hGM-CSF sites may be overwhelmed by other cell types, such as lymphocytes and M, and the initial responding population may eventually be disrupted in the necrotic inflammation observed.
The protein expression levels in vivo that were obtained by ELISA analysis of punch biopsy samples at the sites of injection showed biologically relevant levels of hGM-CSF at 24 hours after injection. Because protein production is a cumulative process by intact, transfected tumor cells with viable mRNA generation, we believe that our system is capable of generating the desired immunologically effective dose of GM-CSF of 24 -48 ng/10 6 cells, as determined in preclinical studies by Berns et al. 73 The intermediate dose effect eliciting the greatest host antitumor immunity was also observed by Abe et al. 50 No toxicity was observed in any animals using our dose injection level of 10 7 cells/site. The i.d. vaccine injection sites were well tolerated by the dogs, and the mild pruritus did not result in any gross lesions that were attributable to excessive scratching or biting of the sites. No alterations in blood or chemistry values were seen, and all subjective behavioral observations (appetite, water consumption, sleep patterns, etc.) were within normal limits. Furthermore, no hGM-CSF was detected in sera at any timepoint.
We believe that the study of hGM-CSF-transfected tumor cell vaccines in dogs provides a valuable translational research model. GM-CSF-transfected cells have been shown in numerous studies to have potent antineoplastic effects, albeit in an indirect manner. However, by increasing the numbers and life spans of critical inflammatory cells, and through the enhancement of host Ag presentation function, deficits in Ag presentation and a costimulation of tumor cells may be overcome. Our research group has previously demonstrated the potent inflammatory and immunological effects of hGM-CSF in the dog model. 27, 51 The Accell device provides a useful method of gene transfer, eliminating the extended cell culture manipulations that were required previously to generate a biologically active, nontoxic, well-tolerated tumor cell vaccine. Our use of control-transfected or nontransfected tumor cells also addresses many concerns regarding the natural immunogenicity of many tumor cell vaccine studies previously conducted in murine models. 75, 76 As a result, we have initiated a phase I clinical ‫ء‬Original vaccination site could not be visually determined; sample was taken from approximate area of vaccination. †Original vaccination site could not be visually determined; sample was taken from approximate area of vaccination instead.
trial using hGM-CSF-transfected, irradiated, autologous tumor cells in dogs with spontaneous melanoma and soft tissue sarcomas.
